Summary

The in vitro toxicology testing market is projected to reach USD 20.97 billion by 2031, growing from an estimated USD 12.69 billion in 2026, at a CAGR of 10.6% during the forecast period. Growth is being driven by increasing use of cell-based assays, 3D culture models, organoids, organ-on-chip systems, high-content screening, automation, and AI-enabled predictive toxicology for early-stage compound screening and safety profiling. The market is further supported by rising pharmaceutical and biotechnology R&D spending, demand for faster and more human-relevant toxicity prediction, outsourcing to CROs, and regulatory momentum to reduce animal testing while improving preclinical decision-making.

“The products segment accounted for a larger share than the services segment in 2025.”
By offering, the products segment accounted for the largest share in the global in vitro toxicology testing market. The products segment led the market because in vitro toxicology workflows depend heavily on recurring product consumption, including assay kits, reagents, cell culture media, sera, buffers, microplates, detection substrates, reference standards, and validated cell models. Unlike services, these products are repeatedly required across every cytotoxicity, genotoxicity, organ toxicity, dermal, ocular, and mechanistic toxicity study.

“North America dominated the in vitro toxicology testing market in 2025.”
North America dominated the in vitro toxicology testing market in 2025, primarily due to the strong presence of pharmaceutical and biotechnology companies, advanced CRO infrastructure, well-funded academic research centers, and early adoption of non-animal safety testing technologies across the US and Canada. The region has high demand for cytotoxicity, genotoxicity, hepatotoxicity, cardiotoxicity, and mechanistic toxicity testing during drug discovery, preclinical development, cosmetics safety assessment, chemical evaluation, and medical device biocompatibility testing. The US also has a mature ecosystem of assay kit suppliers, cell model providers, organ-on-chip companies, high-content screening platforms, and predictive toxicology software developers, supporting broad commercialization of in vitro toxicology products and services. Regulatory modernization initiatives encouraging alternative methods to animal testing further support adoption.
The primary interviews conducted for this report can be categorized as follows:

・By Respondent: Supply Side - 70%; Demand Side 30%
・By Designation: Managers - 45%; CXO & Directors - 30%; and Executives - 25%
・By Region: North America - 40%; Europe - 25%; Asia Pacific - 20%; Latin America - 10%; and Middle East & Africa - 5%

List of Companies Profiled in the Report:
・Thermo Fisher Scientific Inc. (US)
・Merck KGaA (Germany)
・Eurofins Scientific (Luxembourg)
・Laboratory Corporation of America Holdings (US)
・Charles River Laboratories (US)
・SGS SA (Switzerland)
・Bio-Rad Laboratories, Inc. (US)
・Evotec SE (Germany)
・Promega Corporation (US)
・Catalent, Inc. (US)
・Agilent Technologies, Inc. (US)
・Intertek Group plc (UK)
・Revvity (US)
・Inotiv (US)
・BioIVT (US)
・Lonza (Switzerland)
・Creative Biolabs (US)
・Shanghai Medicilon Inc. (China)
・Creative Bioarray (US)
・Aragen Life Sciences Ltd. (India)
・Enzo Biochem Inc. (US)
・Microbac Laboratories, Inc. (US)
・Vimta Labs Ltd. (India)
・Pacific BioLabs Inc. (US)
・MB Research Laboratories (US)

Research Coverage:
This research report categorizes the in vitro toxicology testing market by offering {Products [Reagents & Consumables (Cell Lines & Primary Cells, Culture Reagents, Media & Consumables, 3D Models and Tissue Systems, Other Reagents & Consumables), Assay Kits (Cytotoxicity Assay, Genotoxicity Assay, Organ-Specific Toxicity Assay, Other Assays), Equipment (Detection, Imaging & Analytical Systems (Imaging Systems, Detection Instruments, Other Instruments), Liquid Handling & Automation Systems, Other Equipment), Software & Informatics, and Services; Product - By Toxicity End Point (Organ Toxicity Testing, Cytotoxicity Testing, Genotoxicity Testing, Dermal Toxicity and Skin Irritation, Corrosion and Sensitization, Oxidative Stress and Mechanistic Toxicity, Other Toxicity Endpoints and Tests); Product - By Technology (Cell Culture Technologies, High-Throughput and High-Content Technologies, Omics Technologies, Organotypic and Microphysiological Based Technologies, Other Technologies); Product - By Method (Cell-Based Toxicity Testing Method, Biochemical Toxicity Testing Method, In Silico/Computational Toxicity Testing Method, Ex Vivo Models-Based Toxicity Testing Method, Molecular & Omics-Based Toxicology Method, Other Methods); Product - By End User (Pharmaceuticals & Biotechnology Companies, Consumer Care Companies, Food & Beverages Companies, Cros, Academic And Research Institutes, Other End Users); Service- By Type (Toxicology Testing Service, Biological Model And Assay Development Services, Imaging And Analytical Toxicology Services, Data Analysis, Bioinformatics, And Predictive Toxicology); Service - By Method (Cell-Based Toxicity Testing Method, Biochemical Toxicity Testing Method, In Silico/Computational Toxicity Testing Method, Ex Vivo Models-Based Toxicity Testing Method, Molecular & Omics-Based Toxicology Method, Other Methods); Service - By End User (Pharmaceuticals & Biotechnology Companies, Consumer Care Companies, Food & Beverages Companies, Academic And Research Institutes, Other End Users).
The report’s scope encompasses detailed information regarding major influencing factors such as drivers, trends, challenges, and opportunities shaping the growth of the in vitro toxicology testing market. A comprehensive analysis of key industry players has been conducted to offer insights into their business overview, products, key strategies, collaborations, partnerships, and agreements. The report also covers recent developments, including new product launches, mergers, and acquisitions, in the in vitro toxicology testing market.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall in vitro toxicology testing market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights into the following pointers:
・Analysis of key drivers (Growing industry shift toward non-animal toxicology testing methods, increasing technological advancements), restraints (Limited in vivo-to-in vitro correlation for complex endpoints), opportunities (AI/ML-powered predictive toxicology, increasing focus on drug discovery using in vitro methods, cannabis, e-cigarette, and novel product safety testing), and challenges (Ethical and regulatory challenges in AI-driven toxicology), influencing the growth of the market
・Product/Service Development/Innovation: Detailed insights on newly launched products/services of the in vitro toxicology testing market
・Market Development: Comprehensive information about lucrative markets across varied regions
・Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the in vitro toxicology testing market
・Competitive Assessment: Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Eurofins Scientific (Luxembourg), Laboratory Corporation of America Holdings (US), Charles River Laboratories (US), SGS SA (Switzerland), Bio-Rad Laboratories, Inc. (US), Evotec SE (Germany), Promega Corporation (US), Catalent, Inc. (US), Agilent Technologies, Inc. (US), Intertek Group plc (UK), Revvity (US), Inotiv (US), BioIVT (US), Lonza (Switzerland), Creative Biolabs (US), Shanghai Medicilon Inc. (China), Creative Bioarray (US), Aragen Life Sciences Ltd. (India), Enzo Biochem Inc. (US), Microbac Laboratories, Inc. (US), Vimta Labs Ltd. (India), Pacific BioLabs Inc. (US), and MB Research Laboratories (US), among others, in the market

ページTOPに戻る

Table of Contents

1 INTRODUCTION 60
1.1 STUDY OBJECTIVES 60
1.2 MARKET DEFINITION 60
1.3 MARKET SCOPE 61
1.3.1 MARKETS COVERED 61
1.3.2 INCLUSIONS & EXCLUSIONS 62
1.3.3 YEARS CONSIDERED 63
1.3.4 CURRENCY CONSIDERED 63
1.4 STAKEHOLDERS 63
2 EXECUTIVE SUMMARY 64
2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS 64
2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS 65
2.3 DISRUPTIVE TRENDS SHAPING THE MARKET 66
2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS 67
2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST 68
3 PREMIUM INSIGHTS 69
3.1 IN VITRO TOXICOLOGY TESTING MARKET OVERVIEW 69
3.2 NORTH AMERICA: IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TYPE 70
3.3 IN VITRO TOXICOLOGY TESTING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 71
3.4 IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET SHARE, BY END USER, 2026 VS 2031 (%) 71
4 MARKET OVERVIEW 72
4.1 INTRODUCTION 72
4.2 MARKET DYNAMICS 72
4.2.1 DRIVERS 74
4.2.1.1 Growing Industry Shift Toward Non-Animal Toxicology Testing Methods 74
4.2.1.2 Increasing Technological Advancements 74
4.2.1.3 Rising Pharmaceutical R&D Expenditure and Drug Attrition Costs 74
4.2.2 RESTRAINTS 75
4.2.2.1 Limited In Vivo-to-In Vitro Correlation for Complex Endpoints 75
4.2.2.2 High Cost of Advanced Platforms (Organ-on-Chip, 3D Models) 75
4.2.3 OPPORTUNITIES 75
4.2.3.1 AI/ML-Powered Predictive Toxicology 75
4.2.3.2 Increasing Focus on Drug Discovery Using In Vitro Methods 76
4.2.3.3 Cannabis, E-Cigarette, and Novel Product Safety Testing 76
4.2.4 CHALLENGES 76
4.2.4.1 Ethical and Regulatory Challenges in AI-Driven Toxicology 76
4.3 UNMET NEEDS AND WHITE SPACES 77
4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES 77
4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS 77
5 INDUSTRY TRENDS 79
5.1 PORTER’S FIVE FORCES ANALYSIS 79
5.1.1 THREAT OF NEW ENTRANTS 80
5.1.2 THREAT OF SUBSTITUTES 80
5.1.3 BARGAINING POWER OF BUYERS 80
5.1.4 BARGAINING POWER OF SUPPLIERS 80
5.1.5 INTENSITY OF COMPETITIVE RIVALRY 80
5.2 MACROECONOMIC OUTLOOK 81
5.2.1 INTRODUCTION 81
5.2.2 GDP TRENDS AND FORECAST 81
5.2.3 TRENDS IN GLOBAL IN VITRO TOXICOLOGY TESTING MARKET 81
5.3 VALUE CHAIN ANALYSIS 82
5.4 ECOSYSTEM ANALYSIS 83
5.5 PRICING ANALYSIS 85
5.5.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT, 2025 86
5.5.2 INDICATIVE SELLING PRICE, BY REGION, 2025 86
5.6 KEY CONFERENCES & EVENTS 87
5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 87
5.8 INVESTMENT/FUNDING ACTIVITY 88
5.9 IMPACT OF 2025 TARIFFS—IN VITRO TOXICOLOGY TESTING MARKET 89
5.9.1 INTRODUCTION 89
5.9.2 KEY TARIFF RATES 89
5.9.3 PRICE IMPACT ANALYSIS 90
5.9.4 IMPACT ON COUNTRIES/REGIONS 90
5.9.4.1 North America 90
5.9.4.2 Europe 91
5.9.4.3 Asia Pacific 91
5.9.5 IMPACT ON END-USE INDUSTRIES 91
5.9.5.1 Pharmaceutical and biotechnology companies 92
5.9.5.2 CROs 92
5.9.5.3 Academic & Research Institutes 92
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS 93
6.1 KEY TECHNOLOGIES 93
6.1.1 CELL CULTURE TECHNOLOGIES 93
6.1.2 OMICS TECHNOLOGIES 93
6.2 ADJACENT TECHNOLOGIES 94
6.2.1 COMPUTATIONAL TOXICOLOGY AND AI 94
6.3 COMPLEMENTARY TECHNOLOGIES 94
6.3.1 LAB-ON-A-CHIP (LOC)/ORGAN-ON-A-CHIP (OOC) SYSTEMS 94
6.4 TECHNOLOGY/PRODUCT ROADMAP 95
6.5 PATENT ANALYSIS 95
6.5.1 TOP APPLICANTS/OWNERS (COMPANIES) FOR IN VITRO TOXICOLOGY TESTING PATENTS, 2015–2025 96
6.6 FUTURE APPLICATIONS 97
6.7 IMPACT OF AI/GEN AI ON IN VITRO TOXICOLOGY TESTING MARKET 97
6.7.1 TOP USE CASES AND MARKET POTENTIAL 98
6.7.2 CASE STUDIES OF AI IMPLEMENTATION IN IN VITRO TOXICOLOGY TESTING MARKET 99
6.7.3 INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS 99
6.7.4 CLIENTS’ READINESS TO ADOPT GENERATIVE AI IN IN VITRO TOXICOLOGY TESTING MARKET 99
7 SUSTAINABILITY AND REGULATORY LANDSCAPE 102
7.1 REGIONAL REGULATIONS AND COMPLIANCE 102
7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 102
7.1.2 REGULATORY FRAMEWORK 105
7.1.3 INDUSTRY STANDARDS 106
7.2 SUSTAINABILITY IMPACT AND REGULATORY POLICY INITIATIVES 107
7.3 CERTIFICATIONS, LABELING, & ECO-STANDARDS 108
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR 110
8.1 DECISION-MAKING PROCESS 110
8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA 110
8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS 110
8.2.2 KEY BUYING CRITERIA, BY END USER 111
8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES 112
8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES 113
8.5 MARKET PROFITABILITY 113
9 IN VITRO TOXICOLOGY TESTING MARKET, BY OFFERING 114
9.1 INTRODUCTION 115
9.2 PRODUCTS 115
9.2.1 GROWING ADOPTION OF ADVANCED ASSAY PRODUCTS TO SUPPORT GROWTH 115
9.3 SERVICES 119
9.3.1 INCREASING FOCUS ON OUTSOURCING TOXICOLOGY TO AID GROWTH 119
10 IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TYPE 123
10.1 INTRODUCTION 124
10.2 REAGENTS & CONSUMABLES 124
10.2.1 CULTURE REAGENTS, MEDIA, AND CONSUMABLES 127
10.2.1.1 Increasing adoption of IVTT workflows and recurring use of reagents to support growth 127
10.2.2 3D MODELS & TISSUE SYSTEMS 131
10.2.2.1 Support from regulatory agencies and wide usage to drive market growth 131
10.2.3 CELL LINES & PRIMARY CELLS 134
10.2.3.1 Emphasis on personalized medicine and driving quality improvement in commercially available cells to propel market 134
10.2.4 OTHER REAGENTS & CONSUMABLES 137
10.3 ASSAY KITS 140
10.3.1 ORGAN-SPECIFIC TOXICITY ASSAYS 143
10.3.1.1 Market is driven well-documented failure of generic cytotoxicity screens to predict organ-level adverse effects 143
10.3.2 CYTOTOXICITY ASSAYS 146
10.3.2.1 Cytotoxicity assays are the most universally applied assays in IVTT 146
10.3.3 GENOTOXICITY ASSAYS 149
10.3.3.1 Stringent regulatory mandates to support growth 149
10.3.4 OTHER ASSAYS 152
10.4 EQUIPMENT 155
10.4.1 DETECTION, IMAGING, AND ANALYTICAL SYSTEMS 158
10.4.1.1 Detection instruments 161
10.4.1.1.1 Growth is supported by the increasing volume of HTS workflows in pharmaceutical R&D and expanding use of functional safety pharmacology assays 161
10.4.1.2 Imaging systems 164
10.4.1.2.1 Demand for imaging systems in IVTT is being driven by the transition from single-endpoint to multiparametric, image-based toxicity assessment 164
10.4.1.3 Other instruments 168
10.4.1.4 Liquid handling & automation systems 171
10.4.1.4.1 Ease offered by automation and the important role of liquid handling in workflow to aid growth 171
10.4.1.5 Other instruments 174
10.5 SOFTWARE & INFORMATICS 177
10.5.1 DEMAND FOR AI/ML CAPABILITIES WITH TOXICOLOGY DATA TO DRIVE GROWTH 177
11 IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TOXICITY ENDPOINT & TEST 181
11.1 INTRODUCTION 182
11.2 ORGAN TOXICITY TESTING 182
11.2.1 HEPATOTOXICITY 185
11.2.1.1 Regulatory mandates and focus on developing advanced liver models to support growth 185
11.2.2 OCULAR TOXICITY 189
11.2.2.1 Demand for cosmetics application to aid growth 189
11.2.3 CARDIOTOXICITY 192
11.2.3.1 Regulatory imperative for comprehensive cardiac safety profiling to drive growth 192
11.2.4 NEUROTOXICITY 195
11.2.4.1 Focus on developmental neurotoxicity and the expanding CNS drug pipelines to support growth 195
11.2.5 OTHER TOXICITY END POINTS 198
11.3 CYTOTOXICITY TESTING 201
11.3.1 A GROWING NUMBER OF NEW CLINICAL ENTITIES AND THE EXPANSION OF HTS PROGRAMS DRIVES MARKET 201
11.4 DERMAL TOXICITY & SKIN IRRITATION, CORROSION, AND SENSITIZATION 204
11.4.1 RISING AWARENESS AND BAN ON ANIMAL TESTING TO PROPEL MARKET 204
11.5 GENOTOXICITY TESTING 207
11.5.1 MANDATORY REQUIREMENT IN DRUG APPLICATIONS SUPPORTS MARKET GROWTH 207
11.6 OXIDATIVE STRESS AND MECHANISTIC TOXICITY 210
11.6.1 SHIFT TOWARD MECHANISTIC UNDERSTANDING TO DRIVE DEMAND FOR ASSAYS 210
11.7 OTHER TOXICITY ENDPOINTS & TESTS 213
12 IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY TECHNOLOGY 216
12.1 INTRODUCTION 217
12.2 CELL CULTURE TECHNOLOGIES 217
12.2.1 ADVANCING ADOPTION OF HUMAN-RELEVANT CELL CULTURE MODELS TO SUPPORT MARKET GROWTH 217
12.3 HIGH-THROUGHPUT & HIGH-CONTENT TECHNOLOGIES 220
12.3.1 EXPANDING HIGH-THROUGHPUT TOXICITY SCREENING TO ACCELERATE EARLY SAFETY ASSESSMENT 220
12.4 ORGANOTYPIC & MICROPHYSIOLOGICAL-BASED TECHNOLOGIES 223
12.4.1 GROWING FOCUS ON HUMAN-RELEVANT TOXICITY PREDICTION TO SUPPORT GROWTH 223
12.5 OMICS TECHNOLOGIES 226
12.5.1 INCREASING INTEGRATION OF OMICS-BASED TOXICOLOGY TO IMPROVE MECHANISTIC RISK ASSESSMENT 226
12.6 OTHER TECHNOLOGIES 229
13 IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY METHOD 232
13.1 INTRODUCTION 233
13.2 CELL-BASED TOXICITY TESTING 233
13.2.1 CELL-BASED TOXICITY TESTING HOLDS LARGEST MARKET SHARE 233
13.3 BIOCHEMICAL TOXICITY TESTING METHOD 237
13.3.1 SPEED AND REPRODUCIBILITY TO AID GROWTH 237
13.4 MOLECULAR & OMICS-BASED TOXICOLOGY METHOD 240
13.4.1 TRANSITION FROM SINGLE-ENDPOINT TO SYSTEMS-LEVEL TOXICOLOGICAL ASSESSMENT DRIVES DEMAND GROWTH 240
13.5 EX VIVO MODEL-BASED TOXICITY TESTING METHOD 243
13.5.1 INCREASING AVAILABILITY OF HUMAN DONOR TISSUE TO SUPPORT ADOPTION 243
13.6 IN SILICO/COMPUTATIONAL TOXICITY TESTING METHOD 247
13.6.1 ESCALATING COST AND TIME PRESSURES OF PHYSICAL TESTING TO AID GROWTH 247
13.7 OTHER METHODS 250
14 IN VITRO TOXICOLOGY TESTING PRODUCTS MARKET, BY END USER 253
14.1 INTRODUCTION 254
14.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 254
14.2.1 RISING GLOBAL PHARMACEUTICAL R&D EXPENDITURE SUPPORTING DRUG DISCOVERY EFFORTS 254
14.3 CONSUMER CARE COMPANIES 258
14.3.1 ANIMAL TESTING BANS TO SUPPORT SEGMENT GROWTH 258
14.4 CROS 261
14.4.1 HIGH CAPITAL AND OPERATIONAL COSTS OF MAINTAINING ADVANCED TECHNOLOGIES SUPPORT OUTSOURCING TO CROS 261
14.5 ACADEMIC & RESEARCH INSTITUTES 265
14.5.1 INCREASING GOVERNMENT FUNDING FOR ALTERNATIVE TESTING RESEARCH TO AID GROWTH 265
14.6 FOOD & BEVERAGE COMPANIES 268
14.6.1 GROWTH OF FUNCTIONAL FOODS, PLANT-BASED PROTEINS, AND NOVEL INGREDIENTS DRIVES DEMAND FOR TESTING 268
14.7 OTHER END USERS 272
15 IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY TYPE 276
15.1 INTRODUCTION 277
15.2 TOXICOLOGY TESTING SERVICES 277
15.2.1 ORGAN-SPECIFIC TOXICITY SERVICES 280
15.2.1.1 High reliance on outsourced services and growing demand for cardiotoxicity testing to drive market 280
15.2.2 CYTOTOXICITY TESTING SERVICES 283
15.2.2.1 Growing preclinical pipelines requiring cytotoxicity testing to propel demand 283
15.2.3 GENOTOXICITY TESTING SERVICES 286
15.2.3.1 Expanding impurity testing obligations to drive market 286
15.2.4 OTHER TOXICITY TESTING SERVICES 289
15.3 BIOLOGICAL MODEL & ASSAY DEVELOPMENT SERVICES 292
15.3.1 STRONG GROWTH SUPPORTED BY RISING DEMAND FOR APPLICATION-SPECIFIC MODELS AND ASSAYS 292
15.4 IMAGING & ANALYTICAL TOXICOLOGY SERVICES 295
15.4.1 CAPITAL-INTENSIVE INSTRUMENTATION AND SPECIALIZED REQUIREMENTS SUPPORT OUTSOURCING 295
15.5 DATA ANALYSIS, BIOINFORMATICS, AND PREDICTIVE TOXICOLOGY 298
15.5.1 INTEGRATION OF AI/ML AND RISING DATA COMPLEXITY PROPEL DEMAND 298
16 IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY METHOD 302
16.1 INTRODUCTION 303
16.2 CELL-BASED TOXICITY TESTING SERVICES 303
16.2.1 HIGH COST AND COMPLEXITY OF MAINTAINING ADVANCED CELL CULTURE INFRASTRUCTURE TO DRIVE GROWTH 303
16.3 BIOCHEMICAL TOXICITY TESTING SERVICES 307
16.3.1 GROWTH OF BIOLOGIC DRUG DEVELOPMENT IS DRIVING DEMAND FOR SPECIALIZED BIOCHEMICAL IMMUNOGENICITY TESTING SERVICES 307
16.4 IN SILICO/COMPUTATIONAL TOXICITY TESTING SERVICES 310
16.4.1 GROWING DATA COMPLEXITY, AI/ML MATURITY, AND REGULATORY ACCEPTANCE DRIVE GROWTH 310
16.5 MOLECULAR & OMICS-BASED TOXICOLOGY SERVICES 313
16.5.1 SPECIALIZED ANALYTICAL EXPERTISE REQUIREMENTS RELATED TO OMICS TO DRIVE GROWTH 313
16.6 EX VIVO MODEL-BASED TOXICITY TESTING SERVICES 317
16.6.1 USE OF EX VIVO MODELS FOR IN VITRO AND IN SILICO VALIDATION TO SUPPORT GROWTH 317
16.7 OTHER SERVICES 320
17 IN VITRO TOXICOLOGY TESTING SERVICE MARKET, BY END USER 323
17.1 INTRODUCTION 324
17.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 324
17.2.1 INCREASING COST AND COMPLEXITY OF MAINTAINING ADVANCED IVTT PLATFORMS IN-HOUSE TO SUPPORT GROWTH 324
17.3 CONSUMER CARE COMPANIES 328
17.3.1 REGULATION MANDATING IN VITRO-ONLY SAFETY ASSESSMENT IS SUPPORTING GROWTH 328
17.4 FOOD & BEVERAGE COMPANIES 331
17.4.1 EXPANDING SCOPE OF FUNCTIONAL FOOD AND ALTERNATIVE PROTEIN SAFETY ASSESSMENT TO SUPPORT GROWTH 331
17.5 ACADEMIC & RESEARCH INSTITUTES 335
17.5.1 OUTSOURCING OF SPECIALIZED SERVICES TO SUPPORT GROWTH 335
17.6 OTHER END USERS 338
18 IN VITRO TOXICOLOGY TESTING MARKET, BY REGION 342
18.1 INTRODUCTION 343
18.2 NORTH AMERICA 343
18.2.1 US 351
18.2.1.1 Growing focus on biomarker discovery and research in structure-based drug design to propel the market 351
18.2.2 CANADA 359
18.2.2.1 Strong support for R&D in pharmaceuticals and proteomics to boost market growth 359
18.3 EUROPE 367
18.3.1 GERMANY 374
18.3.1.1 Well-established pharmaceuticals industry to support market growth 374
18.3.2 UK 382
18.3.2.1 Rising focus on research activities and academia-industry partnerships to drive market 382
18.3.3 FRANCE 390
18.3.3.1 Increasing government funding for proteomics and genomics research to drive market 390
18.3.4 ITALY 398
18.3.4.1 Increasing life sciences research to propel market 398
18.3.5 SPAIN 405
18.3.5.1 Growing chemicals industry to support market growth 405
18.3.6 REST OF EUROPE 413
18.4 ASIA PACIFIC 420
18.4.1 CHINA 429
18.4.1.1 Increasing international pressure to ban animal testing methods to propel the market 429
18.4.2 JAPAN 436
18.4.2.1 Rising demand for technologically advanced research products to drive market 436
18.4.3 INDIA 443
18.4.3.1 Growing focus of universities on avoiding animal testing for cosmetic products to propel the market 443
18.4.4 SOUTH KOREA 451
18.4.4.1 Growing government focus on boosting pharmaceutical spending to propel market growth 451
18.4.5 AUSTRALIA 458
18.4.5.1 Growing pharmaceutical research to help market growth 458
18.4.6 REST OF ASIA PACIFIC 464
18.5 LATIN AMERICA 471
18.5.1 BRAZIL 479
18.5.1.1 Adoption of non-animal testing methods to propel market 479
18.5.2 MEXICO 486
18.5.2.1 Ban on animal testing for cosmetics to support market growth 486
18.5.3 REST OF LATIN AMERICA 493
18.6 MIDDLE EAST 500
18.6.1 GCC COUNTRIES 507
18.6.1.1 Saudi Arabia 515
18.6.1.1.1 Rising pharmaceutical R&D activities and regulatory focus on alternative testing methods to support market growth 515
18.6.1.2 United Arab Emirates (UAE) 522
18.6.1.2.1 Expanding biotechnology ecosystem and growing focus on advanced safety assessment technologies supporting market growth 522
18.6.1.3 Rest of GCC Countries 529
18.6.1.4 Rest of Middle East 536
18.6.2 AFRICA 543
18.6.2.1 Precision medicine initiatives to fuel market growth 543
19 COMPETITIVE LANDSCAPE 550
19.1 OVERVIEW 550
19.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 550
19.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN IN VITRO TOXICOLOGY TESTING MARKET 550
19.3 REVENUE SHARE ANALYSIS 552
19.4 MARKET SHARE ANALYSIS 553
19.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025 555
19.5.1 STARS 555
19.5.2 EMERGING LEADERS 555
19.5.3 PERVASIVE PLAYERS 556
19.5.4 PARTICIPANTS 556
19.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025 557
19.5.5.1 Company footprint 557
19.5.5.2 Region footprint 558
19.5.5.3 Offering footprint 559
19.5.5.4 Technology footprint 560
19.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025 561
19.6.1 PROGRESSIVE COMPANIES 561
19.6.2 STARTING BLOCKS 561
19.6.3 RESPONSIVE COMPANIES 561
19.6.4 DYNAMIC COMPANIES 561
19.6.5 COMPETITIVE BENCHMARKING OF KEY STARTUP/SME PLAYERS 563
19.6.5.1 Competitive benchmarking of key startups/SMEs 564
19.7 COMPANY VALUATION & FINANCIAL METRICS 565
19.7.1 FINANCIAL METRICS 565
19.7.2 COMPANY VALUATION 565
19.8 BRAND/PRODUCT COMPARISON 566
19.9 COMPETITIVE SCENARIO 567
19.9.1 PRODUCT LAUNCHES 567
19.9.2 DEALS 568
19.9.3 EXPANSIONS 568
20 COMPANY PROFILES 569
20.1 THERMO FISHER SCIENTIFIC INC. 569
20.1.1 BUSINESS OVERVIEW 569
20.1.1.1 Products/Services/Solutions offered 570
20.1.1.2 Recent developments 574
20.1.1.2.1 Product launches 574
20.1.1.2.2 Deals 575
20.1.1.2.3 Expansions 575
20.1.1.3 MnM view 576
20.1.1.3.1 Key strengths 576
20.1.1.3.2 Strategic choices 576
20.1.1.3.3 Weaknesses and competitive threats 576
20.1.2 AGILENT TECHNOLOGIES, INC. 577
20.1.2.1 Business overview 577
20.1.2.2 Products/Services/Solutions offered 578
20.1.2.3 Recent developments 580
20.1.2.3.1 Product launches & enhancements 580
20.1.2.3.2 Deals 581
20.1.2.4 MnM view 581
20.1.2.4.1 Key strengths 581
20.1.2.4.2 Strategic choices 581
20.1.2.4.3 Weaknesses and competitive threats 581
20.1.3 MERCK KGAA 582
20.1.3.1 Business overview 582
20.1.3.2 Products/Services/Solutions offered 583
20.1.3.3 Recent developments 585
20.1.3.3.1 Deals 585
20.1.3.4 MnM view 585
20.1.3.4.1 Key strengths 585
20.1.3.4.2 Strategic choices 585
20.1.3.4.3 Weaknesses and competitive threats 585
20.1.4 EUROFINS SCIENTIFIC 586
20.1.4.1 Business overview 586
20.1.4.2 Products/Services/Solutions offered 587
20.1.4.3 Recent developments 594
20.1.4.3.1 Expansions 594
20.1.5 CHARLES RIVER LABORATORIES 595
20.1.5.1 Business overview 595
20.1.5.2 Products/Services/Solutions offered 596
20.1.5.3 Recent developments 600
20.1.5.3.1 Product launches 600
20.1.5.3.2 Deals 600
20.1.5.3.3 Other developments 601
20.1.5.4 MnM view 601
20.1.5.4.1 Key strengths 601
20.1.5.4.2 Strategic choices 601
20.1.5.4.3 Weaknesses and competitive threats 601
20.1.6 LABORATORY CORPORATION OF AMERICA HOLDINGS 602
20.1.6.1 Business overview 602
20.1.6.2 Products/Services/Solutions offered 603
20.1.6.3 Recent developments 606
20.1.6.3.1 Deals 606
20.1.6.3.2 Expansions 606
20.1.6.3.3 Other developments 607
20.1.6.4 MnM view 607
20.1.6.4.1 Key strengths 607
20.1.6.4.2 Strategic choices 607
20.1.6.4.3 Weaknesses and competitive threats 607
20.1.7 SGS SA 608
20.1.7.1 Business overview 608
20.1.7.2 Products/Services/Solutions offered 609
20.1.7.3 Recent developments 612
20.1.7.3.1 Deals 612
20.1.7.3.2 Expansions 612
20.1.8 LONZA 613
20.1.8.1 Business overview 613
20.1.8.2 Products/Services/Solutions offered 614
20.1.9 REVVITY 616
20.1.9.1 Business overview 616
20.1.9.2 Products/Services/Solutions offered 617
20.1.9.3 Recent developments 619
20.1.9.3.1 Product launches 619
20.1.9.3.2 Other developments 619
20.1.10 BIO-RAD LABORATORIES, INC. 620
20.1.10.1 Business overview 620
20.1.10.2 Products/Services/Solutions offered 621
20.1.10.3 Recent developments 623
20.1.10.3.1 Product launches 623
20.1.10.3.2 Deals 624
20.1.11 EVOTEC SE 625
20.1.11.1 Business overview 625
20.1.11.2 Products/Services/Solutions offered 626
20.1.11.3 Recent developments 633
20.1.11.3.1 Deals 633
20.1.11.3.2 Other developments 633
20.1.12 NOVO HOLDINGS 634
20.1.12.1 Business overview 634
20.1.12.2 Products & services offered 634
20.1.13 INTERTEK GROUP PLC 635
20.1.13.1 Business overview 635
20.1.13.2 Products & services offered 637
20.1.14 INOTIV 638
20.1.14.1 Business overview 638
20.1.14.2 Products & services offered 639
20.1.15 PROMEGA CORPORATION 642
20.1.15.1 Business overview 642
20.1.15.2 Products & services offered 642
20.1.15.3 Recent developments 645
20.1.15.3.1 Deals 645
20.2 OTHER PLAYERS 646
20.2.1 BIOIVT 646
20.2.2 CREATIVE BIOLABS 647
20.2.3 MEDICILON 648
20.2.4 CREATIVE BIOARRAY 649
20.2.5 ARAGEN LIFE SCIENCES LTD. 650
20.2.6 ENZO BIOCHEM INC. 652
20.2.7 MICROBAC LABORATORIES, INC. 655
20.2.8 VIMTA LABS LTD. 657
20.2.9 PACIFIC BIOLABS, INC. 658
20.2.10 MB RESEARCH LABORATORIES 659
21 RESEARCH METHODOLOGY 660
21.1 RESEARCH DATA 660
21.1.1 SECONDARY DATA 661
21.1.2 PRIMARY DATA 661
21.2 MARKET SIZE ESTIMATION 662
21.2.1 GLOBAL IN VITRO TOXICOLOGY TESTING MARKET ESTIMATION, 2025 662
21.2.1.1 Key industry insights 666
21.3 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST 667
21.4 MARKET BREAKDOWN AND DATA TRIANGULATION 670
21.5 RESEARCH ASSUMPTIONS 671
21.6 RESEARCH LIMITATIONS 672
21.7 RISK ANALYSIS 672
22 APPENDIX 673
22.1 DISCUSSION GUIDE 673
22.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 678
22.3 CUSTOMIZATION OPTIONS 680
22.4 RELATED REPORTS 680
22.5 AUTHOR DETAILS 681